UArizona receives $6.9 million grant to make advances in skin cancer prevention and treatment

NewsGuard 100/100 Score

Skin cancer is the most common malignancy worldwide, and one in three new cancers diagnosed is a form of skin cancer, according to the Skin Cancer Foundation. This amounts to about 5 million non-melanoma skin cancers in the United States each year.

In response, a team of researchers at the University of Arizona Cancer Center is developing new strategies to prevent and reduce the risk of squamous cell carcinoma, the second most-common form of non-melanoma skin cancer.

To assist that effort, the UArizona Cancer Center recently was awarded a five-year, $6.9 million prestigious Program Project Grant from the National Cancer Institute (NCI), a unit of the National Institutes of Health (NIH).

Clara Curiel-Lewandrowski, MD, director of the Cutaneous Oncology Program and co-director of the Skin Cancer Institute at the UArizona Cancer Center, is principal investigator for the grant which will be funded by the NCI over the next five years.

This award is both an endorsement of the scientific contributions made by the Skin Cancer Institute research team and a true opportunity to make new groundbreaking advances in skin cancer prevention and treatment. This is a stamp of approval that says the University of Arizona Cancer Center is the place with quality and innovative approaches in skin cancer therapeutic prevention research nationwide."

Dr. Clara Curiel-Lewandrowski, principal investigator

The Program Project Grant will assess, in animal models and human studies, the importance of a novel immune protein known as TLR4 that is modulated by solar ultraviolet radiation. The second focus of the grant includes characterization of a cascade of messages within skin cells recently discovered by the team that are found to promote development of skin cancer after exposure to sunlight. An impactful aspect of the award relates to the formulation and testing of topical drugs, i.e., lotions and creams, that effectively can inhibit the action of these proteins ultimately to prevent squamous cell carcinoma formation.

"We are one of the few institutions that has mastered both experimental and clinical studies that effectively mimic the effect of sunlight," Dr. Curiel-Lewandrowski said. "These models allow us to test drugs that can reproducibly and accurately stop or reverse the cellular damage caused by the sun through pilot and Phase 1 clinical trials.

"This highly integrated and translational research-based program project emphasizes the importance of a multidisciplinary and precision-medicine approach for the prevention of squamous cell carcinoma of the skin," Dr. Curiel-Lewandrowski said. "These discoveries also can serve as a model to prevent other epithelial malignancies."

"Skin cancer is a great risk to many people, especially those of us in Arizona," said UArizona President Robert C. Robbins, MD. "The talented, dedicated researchers at the Cancer Center understand the importance of identifying innovative approaches for skin cancer prevention and treatment, and it is a well-deserved honor for this team to receive this prestigious grant. It is important to discover the safest ways to ensure people significantly reduce their risk of skin cancer while enjoying all the sunshine that makes our beautiful state such a wonderful place to live."

The new funding is the latest award for Dr. Curiel-Lewandrowski and the Skin Cancer Institute team, which has been a leader in skin cancer research, treatment and prevention across Arizona and beyond.

"It is important that our community knows that our Skin Cancer Institute is here for them and that our aligned vision is to prevent and cure skin cancer through research, education and clinical care," Dr. Curiel-Lewandrowski said. "We have an exceptional team in place with a common mission: To eradicate skin cancer in Arizona by decreasing skin-cancer incidence, where late diagnosis is not an option, and no lives are lost due to this preventable disease."


The opinions expressed here are the views of the writer and do not necessarily reflect the views and opinions of News Medical.
Post a new comment

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

You might also like...
Study identifies microbiota signatures associated with KRAS mutations in colorectal cancer patients